Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
- PMID: 40152215
- PMCID: PMC12275001
- DOI: 10.1002/mdc3.70060
Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
Keywords: Parkinson's disease; confusion; delirium; foslevodopa; hallucinations.
References
-
- Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa‐foscarbidopa in patients with advanced Parkinson's disease: a randomised, double‐blind, active‐controlled, phase 3 trial. Lancet Neurol 2022;21(12):1099–1109. 10.1016/S1474-4422(22)00400-8. - DOI - PubMed
-
- Nukariya T, Tezuka T, Okusa S, Okochi R, Sakai Y, Nihei Y, et al. Levodopa pharmacokinetics in switching from levodopa/carbidopa intestinal gel to continuous subcutaneous Foslevodopa/Foscarbidopa infusion in a patient with Parkinson's disease: a case report. J Mov Disord 2025. 10.14802/jmd.24247. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources